Jun 27 |
3 Biotech Stocks That Could Make Your Grandchildren Rich
|
Jun 26 |
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
|
Jun 25 |
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
|
Jun 24 |
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
|
Jun 24 |
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
|
Jun 21 |
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
|
Jun 21 |
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
|
Jun 20 |
Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
|
Jun 18 |
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
|
Jun 17 |
Regeneron touts success with bispecific antibody in multiple myeloma trial
|